PuSH - Publikationsserver des Helmholtz Zentrums München

Lomeguatrib increases the radiosensitivity of mgmt unmethylated human glioblastoma multiforme cell lines.

Int. J. Mol. Sci. 22:6781 (2021)
Verlagsversion DOI
Open Access Gold
Creative Commons Lizenzvertrag
Background: Treatment resistance of glioblastoma multiforme to chemo-and radiotherapy remains a challenge yet to overcome. In particular, the O6-methylguanine-DNA-methyltransferase (MGMT) promoter unmethylated patients have only little benefit from chemotherapy treatment using temozolomide since MGMT counteracts its therapeutic efficacy. Therefore, new treatment options in radiotherapy need to be developed to inhibit MGMT and increase radiotherapy response. Methods: Lomeguatrib, a highly specific MGMT inhibitor, was used to inactivate MGMT protein in vitro. Radiosensitivity of established human glioblastoma multiforme cell lines in combination with lomeguatrib was investigated using the clonogenic survival assay. Inhibition of MGMT was analyzed using Western Blot. Cell cycle distribution and apoptosis were investigated to determine the effects of lomeguatrib alone as well as in combination with ionizing radiation. Results: Lomeguatrib significantly decreased MGMT protein and reduced radiation-induced G2/M arrest. A radiosensitizing effect of lomeguatrib was observed when administered at 1 µM and increased radioresistance at 20 µM. Conclusion: Low concentrations of lomeguatrib elicit radiosensitization, while high concentrations mediate a radioprotective effect.
Altmetric
Weitere Metriken?
Zusatzinfos bearbeiten [➜Einloggen]
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Schlagwörter Glioblastoma ; Lomeguatrib ; Mgmt ; Radiosensitivity ; Radiotherapy; Temozolomide Plus O-6-benzylguanine; Central-nervous-system; Recurrent; Alkyltransferase; Inactivation; Resistance; Cycle; Dna; Repair; Glioma
ISSN (print) / ISBN 1422-0067
e-ISSN 1661-6596
Quellenangaben Band: 22, Heft: 13, Seiten: , Artikelnummer: 6781 Supplement: ,
Verlag MDPI
Verlagsort Basel
Begutachtungsstatus Peer reviewed
Förderungen Medical Faculty of TUM
German Consortium for Translational Cancer Research